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Abstract 
 
Cannabis has been used for recreational purposes around 
the world. It is derived from the plant cannabis sativa which 
has various other compounds known as cannabinoids. Most 
common form of cannabis used for recreational purpose is 
marijuana, which is prepared from dried flowering tops and 
leaves. The primary psychoactive component is delta 9-
tetrahydrocannabinol (δ-9THC), which exerts its 
physiological and psychological effects through its 
interaction with CB1 and CB2 receptors. Smoking is the 
most commonly used method with onset of effects within 
minutes after inhalation. Oral ingestion of cannabis has 
varied absorption with delayed onset but longer duration of 
action. Urine drug screen is the most common method for 
detecting cannabis use. Other cannnabionoids such as 
cannabidiol have been utilized for medicinal purpose and 
research is ongoing to fully understand its role in treatment 
of various health conditions. Synthetic cannabis has 
emerged as drug of abuse over recent years and poses 
greater challenges due to serious physiological and 
psychological effects and inability to be detected in 
standard screening tests.  
 
Keywords: Cannabis, marijuana, cannabinoids, CB 
receptors, CB2 receptors, delta 9-tetrahydrocannabinol  
(δ-9THC), synthetic cannabinoids 
 
 
Introduction 
 
Cannabis has been used for recreational purpose 
around the world for many decades. Its use however 
has increased in recent years among adolescents and 
young adults. Much of this increase seems to correlate 
with low risk perception (1, 2). The primary 
psychoactive constituent of cannabis is delta 9-
tetrahydrocannabinol (δ-9THC) known to have 
various physiological and psychological effects. 
Chronic use leads to dependence and behavioral 
disturbances (3). Multiple studies have explored 
effects of cannabis on various health conditions, but 
its medicinal use is currently limited (3, 4). Debate 
exits over decriminalization and legalization of 
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cannabis with potential to have varied consequences 
(5). This paper describes main cannabinoids, their 
mechanism of action and metabolism in humans. 
 
 
Phyto-cannabinoids 
 
Cannabis is derived from a female plant Cannabis 
sativa which contains many compounds known as 
phyto-cannabinoids or commonly cannabinoids. The 
principal cannabinoids are delta 9-
tetrahydrocannabinol (δ-9THC), cannabidiol (CBD) 
and cannabinol (CBN) (4). THC initially isolated in 
1964, is a primary psychoactive agent and has been 
widely studied (6, 7).Over the years, many new 
cannabinoid and non- cannabinoid compounds in the 
plant have been discovered (4). The number of 
cannabinoids identified since 2005 has increased from 
70 to 104. Other known compounds in the plant have 
also increased from 400 to 650 (4). The content of 
THC varies in different sources and preparations of 
cannabis. Its content is highest in the flowering tops 
and subsequently declines in the leaves, stem and 
seeds of the plant (8). Most common form of cannabis 
that is used for recreational purpose is Marijuana with 
THC content from 0.5% to 5%. It is prepared from the 
dried flowering tops and leaves (6-8). Another form 
of cannabis is hashish with THC content 2–20% and 
is derived from dried cannabis resin and compressed 
flowers (9). The potency of cannabis products has 
increase significantly from approx. 3% to 12-16% or 
higher (percent THC weight/per dry weight of 
cannabis) over the past decades due to sophisticated 
cultivation and plant breeding techniques. The 
concentration of THC can also reach about 80% using 
butane hash oil (4). In the 1960’s and 1970’s, a 
cannabis product for example contained about 10 mg 
of THC. But, current joint made of other subspecies 
of cannabis may contain about 150 mg of THC. 
Current generation of cannabis user may be exposed 
to higher concentrations of THC as compared to those 
who used cannabis decades earlier (8). 
Cannabidiol (CBD) is a non-psychoactive 
cannabinoid obtained from the plant. Over the years, 
it has drawn much attention due to its 
pharmacological activity and therapeutic use (10). 
CBD is found to have neuroprotective, analgesic, 
sedative, anti-emetic, anti-spasmodic, anti- anxiety 
and anti-inflammatory properties. Research is 
ongoing to understand its role in treatment of various 
health conditions (10, 11). 
 
 
Mechanism of action 
 
Cannabinoids are known to exert their physiological 
action through G protein coupled receptors known as 
CB1 and CB2. These receptors were initially 
identified in 1990s and have been extensively studied 
(12). Activation of these receptors leads to inhibition 
of adenylyl cyclase resulting in decreased production 
of cAMP and changes in ion channel activity. 
Through these receptors, cannabinoids hyperpolarize 
neurons by closing voltage-dependent calcium 
channels and activate potassium channels (13). CB1 
receptors are present in both central and peripheral 
nervous system. They are mostly present in region of 
brain associated with memory, cognition, reward, 
anxiety, pain perception, movement (12-14). These 
include cortex, hippocampus, olfactory area, basal 
ganglia, cerebellum and spinal cord. Few CB1 
receptors are found in the brainstem and thus 
administration of cannabinoids is not associated with 
respiratory depression unlike opioids (8, 13, 14). CB1 
receptor activation has also shown to modulate 
neurotransmitters in the brain, including glutamate, γ-
amino butyric acid (GABA), opioids, dopamine, and 
serotonin, resulting in varied effects (8, 9). Role of 
serotonin receptor 5-HT2A in causing some of 
specific effects of THC such as memory deficits, 
anxiolytic-like effects, and social interaction has been 
reported (15). CB2 receptors are present in the cells of 
immune system predominantly in the spleen and 
macrophages and appear to play role in modulation of 
cytokine release and immune cell migration (14).  
 
 
Endocannabinoids 
 
Endocannabinoids are endogenous compounds 
discovered in the 1990s that interact with cannabinoid 
receptors and produce similar effects as cannabis (10). 
The two main endogenous compounds are 
anandamide (from the Sanskrit word ananda, meaning 
bliss) and 2-arachidonoylglycerol (2AG) (10). These 
are derivative of the fatty acid arachidonic acid 
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related to the prostaglandins. Anandamide is partial 
agonist for both CB1 and CB2 receptors with CB1 
efficacy higher than CB2. It produces similar effects 
to δ-9THC, but is less potent and has shorter half-life 
due to rapid metabolism (9, 16). 2-
Arachidonoylglycerol was originally identified in 
intestinal tissue and is found at much higher levels 
than anandamide in the brain. 2-AG is thought to be 
the main endogenous agonist for both CB1 and CB2 
receptors (16). Endocannabinoids also interact with 
other G protein coupled receptor and ion channels. 
Some of the known ion channel are vanilloid 
receptor-type 1 (TRPV1) activated by anandamide. 
Other receptors are several types of potassium 
channels, alpha7 nicotinic receptors and 5-HT3 
receptors (10, 11). The endocannabinoid system 
comprised of endocannabinoids and its  
receptors is thought to mediate various physiological 
processes and are implicated in health and disease 
(16). 
 
 
Absorption of cannabis 
 
The tetrahydrocannabinol and other cannabinoids 
have varied absorption and effects depending on dose, 
route of administration and vehicle. Further 
physiological factors such as metabolism and 
excretion can influence drug concentrations and its 
subsequent effects (11). Smoking is most common 
and widely used method. After inhalation, THC is 
rapidly absorbed through lungs and reaches brain 
quickly with physiological and psychological effects 
becoming apparent within seconds to minutes (10, 
17). The effects then reach a plateau that can last 2–4 
h before slowly declining. While, the amount of THC 
absorbed is higher with inhalation, the bioavailability 
varies according to the depth of inhalation, puff 
duration and breath-hold (17). Absorption of THC is 
variable when ingested. When taken orally, some of 
the THC is degraded by liver due to first pass 
metabolism and converted to 11-hydroxy δ-9THC, 
which is also a psychoactive agent (10, 17). The 
concentration of 11-hydroxy δ-9THC is thus higher in 
blood after ingestion than inhalation and may 
contribute to some of the psychological effects (17). 
With oral ingestion, onset of effect and peak 
concentration of THC in blood is much delayed (1-
2h) (11). Slow gastrointestinal absorption prolongs 
the duration of action that may last several hours (8, 
9, 11). Other routes of administration for cannabis 
such as oro-mucosal, rectal and transdermal have 
been explored and studied. These routes of 
administration increase bioavailability of THC by 
avoiding first pass metabolism in the liver. Such 
forms may be beneficial for therapeutic uses but 
further research is needed (11).  
 
 
Distribution 
 
Cannabinoids are highly lipophilic and get distributed 
in adipose tissue, liver, lung and spleen (9). Following 
assimilation in blood, concentration of THC in plasma 
decreases due to peripheral redistribution particularly 
in adipose tissues. Sequestration in adipose tissue 
prolongs elimination half- life that can last for several 
days (8, 11). From the adipose tissue, THC gets 
slowly released into the blood stream and other body 
compartments including the brain. Cannabinoids also 
cross the placenta, entering into fetal circulation and 
secreted in breast milk (9). 
 
 
Metabolism and elimination 
 
THC is metabolized in the liver by microsomal 
hydroxylation and oxidation using enzymes of 
Cytochrome P 450 Complex generating more than 
100 metabolites (18, 19). As a result of hydroxylation, 
THC generates a psychoactive compound 11-hydroxy 
δ 9_Tetra hydrocannabinol (11-OH-THC). Further, 
11-OH-THC is oxidized by microsomal alcohol 
dehydrogenase and aldehyde oxygenase to produce 
the non-psychoactive metabolite, THCCOOH (11). 
The majority of cannabinoids (80-90%) are excreted 
within five days as hydroxylated and carboxylated 
metabolites (18). The elimination of metabolites is 
mostly through feces (65%) and approximately 20% 
in urine (17). Among the major metabolites, 11-OH-
THC is predominantly excreted in feces and 
THCCOOH is excreted in urine mainly as a 
glucuronic acid conjugate. This particular metabolite 
has been utilized for diagnostic purposes for detection 
of cannabis in urine (17). 
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Detection and analysis of cannabis 
 
Cannabinoids can be detected in urine, blood, saliva, 
hair and nail using various analytical techniques (20). 
These techniques are utilized to measure cannabinoids 
for research studies, drug treatment and employment 
related drug screening. Various chromatographic 
techniques such as thin layer chromatography (TLC), 
high performance thin layer chromatography 
(HPTLC), gas chromatography-mass spectrometry 
(GC-MS), high-performance liquid chromatography-
mass spectrometry (HPLC- MS) have been utilized 
for detection and quantitation of cannabis metabolites 
(17). The preferred sample for screening is urine to 
check for presence of urine metabolites particularly 
glucuronic acid conjugate of THCCOOH (20). The 
main techniques utilized for urine drug screening are 
immunoassay and gas chromatography-mass 
spectrometry (GC-MS). Immunoassays are the most 
common method for initial screening while GC-MS is 
used for confirmation (21, 22). The cut off limit for 
cannabis metabolites in immunoassay is 50ng/ml; it is 
15 ng/ml for GC-MS. Detection of metabolites in 
urine varies depending on frequency and duration of 
cannabis use. It can be detected anywhere from 3 days 
(single use) up to 30 days or longer (long term heavy 
smoker) (22). 
Detection of THC and its metabolites is 
influenced by various other factors in addition to 
sensitivity and specificity of assays. These factors 
include route of administration, amount of 
cannabinoids consumed and absorbed, body fat 
content, rate of metabolism and excretion, time of 
specimen collection (9, 20). 
There has been growing interest in utilization of 
oral fluids as an alternative biological specimen for 
detection of drugs in forensic and clinical settings 
(23). Studies have shown oral fluids to be simple, 
non-invasive method of specimen collection with 
advantages of observed specimen collection, making 
adulteration difficult. It has shown to have stronger 
correlation with blood than urine concentration of 
cannabis metabolites and can detect recent exposure 
(23). It also offers ease of multiple sample collections 
and lower biohazard risk of specimen collection. 
Currently, research on oral fluids in ongoing and 
further evaluation is needed before implementing it a 
drug screening test (23). 
Synthetic cannabinoids 
 
Synthetic cannabinoids are a heterogeneous group of 
compounds originally synthesized for research 
purpose to explore endogenous cannabinoid system 
for possible therapeutic use (24). However, these 
compounds became drugs of abuse and were 
marketed as “designer drugs”. In the 2000s, synthetic 
cannabinoids were sold under brand names such as 
“spice” and “K2,” labeled as herbal incense. These 
became very popular drugs of abuse as they could not 
be detected by standard screening tests (25). 
The synthetic cannabinoids acts on cannabinoid 
receptors and have greater affinity to CB1 than CB2 
receptors. Both animal and in vitro studies have 
shown that synthetic cannabinoids are 2-100 times 
more potent than THC (25). Synthetic cannabinoids 
are metabolized in the liver via conjugation and 
oxidation pathways and have longer elimination half- 
life (24, 25). Use of synthetic cannabinoids has 
resulted in medical and psychiatric emergencies due 
to their intense physiological and psychological 
effects. Some of the common adverse effects include 
seizures, myocardial infarction, acute renal failure, 
anxiety, agitation, psychosis, suicidal ideation, and 
cognitive impairment. Long-term or residual effects 
are currently unknown (26, 27).  
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